Agilent Technologies Inc (A) was Upgraded by Morgan Stanley to ” Overweight”. Earlier the firm had a rating of “Equal-Weight ” on the company shares. Morgan Stanley advised their Clients and Investors in a research report released on Mar 15, 2017.
Based on several research reports , Agilent Technologies Inc was Upgraded by Morgan Stanley to ” Overweight” on Mar 15, 2017. Deutsche Bank Initiated Agilent Technologies Inc on Jan 18, 2017 to “Buy”, Price Target of the shares are set at $54.Company shares were Upgraded by Barclays on Jan 4, 2017 to ” Overweight”, Firm has raised the Price Target to $ 51 from a previous price target of $48 .
Several company insiders have filed Insider transactions , on Feb 21, 2017, Patrick Kaltenbach (Sr Vice President) sold 3,771 shares at $51.68 per share price. According to the SEC, on Feb 16, 2017, Didier Hirsch (Sr. VP and CFO) sold 22,258 shares at $51.50 per share price. On Dec 12, 2016, Mark Doak (Sr. Vice President) sold 3,969 shares at $46.00 per share price, according to the Form-4 filing with the securities and exchange commission.
On the company’s financial health, Agilent Technologies Inc reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Feb 14, 2017. Analyst had a consensus of $0.49. The company had revenue of $1067.00 million for the quarter, compared to analysts expectations of $1047.97 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.
Agilent Technologies Inc opened for trading at $53.31 and hit $54.82 on the upside on Wednesday, eventually ending the session at $54.1, with a gain of 3.62% or 1.89 points. The heightened volatility saw the trading volume jump to 41,17,983 shares. Company has a market cap of $17,436 M.
Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.